CSIMarket
 
Epizyme Inc.  (EPZM)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 167
 Employees -
 Revenues (TTM) (Millions $) 53
 Net Income (TTM) (Millions $) -208
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Epizyme Inc.
Epizyme Inc. is a biopharmaceutical company based in the United States. The company focuses on the discovery, development, and commercialization of novel personalized therapeutics for patients with genetically defined cancers. Epizyme's approach involves targeting specific gene mutations and enzymatic pathways to develop innovative therapies. They create small molecule inhibitors designed to modulate the activity of these enzymes, potentially leading to the suppression or elimination of cancer cells. The goal is to provide patients with more effective and individualized treatment options. Epizyme has multiple drug candidates in its pipeline and collaborates with other pharmaceutical companies to advance its research and development efforts.


   Company Address: 400 Technology Square, 4th Floor Cambridge 2139 MA
   Company Phone Number: 229-5872   Stock Exchange / Ticker: NASDAQ EPZM
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Neurogene Inc

Revenue were $0 million at the Neurogene Inc in financial time-frame closing December 31 2023

For the financial time-frame closing December 31 2023 NGNE reached zero gain of $0.00 per share compare to $-6.06 a year ago and from $-0.41 per share from the previous financial reporting period. The revenue remained unchanged to $0.00 million from $0.00 million in the similar financial reporting period a year ago and sequentially from $0.00 million.

Eyenovia Inc

The Major Pharmaceutical Preparations company released Revenue of $0.002589 million, in thefourth quarter of 2023 financial report

EYEN proclaimed $0.002589 million, in Revenue in the October to December 31 2023 fiscal time-frame.

Avenue Therapeutics Inc

Among many companies, the ATXI reported as well its fourth quarter of 2023 performance

Following the leaders in the Major Pharmaceutical Preparations industry, some lesser known companies are publishing the numbers. ATXI told it has clinched operating loss of $-2.12 million, for the fourth quarter of 2023.

Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.






 

Epizyme's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com